Aug. 2 at 8:43 PM
The interesting part about
$ABCL is the platform, not just one drug.
If Hansen’s vision plays out, the goal is to build a repeatable engine that can keep pushing more candidates into the clinic and toward approvals. ABCL635, follow-up programs, and the company’s discovery technologies are what I’m watching.
The next couple of years could be very important for proving whether this platform can scale.
